(33) found that 34.2% of ER+, PR+ primary breast cancer patients developed ER-, PR- metastatic tumors, and 21.9% of HER2-negative primary breast cancer patients exhibited HER2+ metastatic tumors. Here, ERBB2 is linked to metastatic neoplasm.